Source comparison
Tesamorelin + Ipamorelin Blend: Pharmacokinetic Comparison
Plasma Half-Life ~26 minutes ~2 hours Biphasic GH pulse: rapid initiation + sustained elevation The half-life mismatch is the synergy. Tesamorelin clears before receptor desensitization, ipamorelin sustains without feedback inhibition Time to Peak GH 15–30 min
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~26 minutes
- ~2 hours
- Biphasic GH pulse: rapid initiation + sustained elevation
- The half-life mismatch is the synergy. Tesamorelin clears before receptor desensitization, ipamorelin sustains without feedback inhibition
- Time to Peak GH
- 15–30 minutes
- 30–45 minutes
- Peak occurs at 20–35 minutes, plateau extends to 90–120 minutes
- Single-agent protocols miss the plateau phase. The blend captures both peak and duration
- Receptor Selectivity
- GHRH receptor (anterior pituitary)
- GHS-R1a (ghrelin receptor, selective)
- Dual-pathway activation without cortisol or prolactin elevation
- Ipamorelin's selectivity ratio (1.3 nM Ki for GHS-R1a) is why the blend avoids the appetite and cortisol spikes of older ghrelin mimetics
- Feedback Inhibition Risk
- Low (rapid clearance)
- Moderate (sustained receptor occupancy)
- Minimal when dosed ≤ twice daily at 8–12 hour intervals
- Protocols exceeding twice-daily dosing show diminishing pulse amplitude after 3–4 weeks
- Optimal Dosing Interval
- Single daily or twice daily
- Twice daily
- 8–12 hours between administrations
- Shorter intervals trigger receptor downregulation; longer intervals reduce exogenous pulse contribution